LXRX Q2 2023 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$317,000+805.7% YoY

Gross Profit

$309,00097.5% margin

Operating Income

-$44M-13955.8% margin

Net Income

-$45M-14165.3% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+1220.8%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$317M

Total Liabilities

$130M

Stockholders' Equity

$186M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$317,000	$35,000	+805.7%
Gross Profit	$309,000	$35,000	+782.9%
Operating Income	-$44M	-$24M	-84.3%
Net Income	-$45M	-$25M	-82.6%